Fig. 3From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancerThe analysis of mOS in different post-osimertinib treatment groups. A The mOS was stratified by different post-osimertinib treatments. B Univariate COX regression analysis by baseline characteristics for mOSBack to article page